Lexotanil (Bromazepam)

Bromazepam enhances the activity of the neurotransmitter GABA by binding to a specific site on the GABA‑A receptor. This positive allosteric modulation increases chloride ion flow into neurons, producing hyperpolarisation and reducing neuronal excitability, which results in an overall anxiolytic effect.

The appropriate dose of Lexotanil is determined by the prescribing clinician based on the severity of anxiety, patient age, weight, and overall health status. Dosage may be adjusted during treatment, and patients should follow the individualized regimen provided by their healthcare professional.

Safety of bromazepam in pregnancy and lactation has not been definitively established. It is generally avoided unless the potential benefit outweighs the risk. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss alternatives and risks with their healthcare provider.

To order Lexotanil, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Lexotanil (bromazepam) is similar to other benzodiazepines such as diazepam or lorazepam in its anxiolytic action, but it has a relatively intermediate half‑life and potency. Choice among agents depends on factors like duration of action needed, patient metabolism, and specific clinical scenarios.

Store Lexotanil at ambient temperature, preferably below 25 °C. Keep the tablets in the original container, protect them from moisture, heat and direct sunlight, and ensure the packaging remains tightly closed until use.

Lexotanil is taken orally. The tablet should be swallowed whole with a glass of water, preferably with or without food as directed by the prescriber. Patients should not crush, chew, or split the tablet unless specifically instructed.

Serious risks include respiratory depression, especially when combined with other depressants; development of physical dependence and withdrawal seizures upon abrupt discontinuation; paradoxical reactions such as increased anxiety or aggression; and severe hypotension or allergic reactions. Any concerning symptoms should be reported to a healthcare professional immediately.

Lexotanil should be avoided in patients with severe respiratory insufficiency, acute narrow‑angle glaucoma, known hypersensitivity to bromazepam or other benzodiazepines, and in individuals with a history of severe dependence on CNS depressants. Use in children and adolescents is generally not recommended unless specifically indicated by a specialist.